Tenpoint and Visus Complete Merger

Tenpoint Therapeutics and Visus Therapeutics announced the completion of their merger.

“As we relaunch Tenpoint as a combined entity with Visus, we are excited to lead with a robust ophthalmology pipeline, starting with Brimochol PF, a near-term therapeutic medicine for presbyopia alongside other innovative therapies to treat cataract and geographic atrophy,” said Henric Bjarke, who has been appointed Chief Executive Officer of the newly merged company. “With our combined teams, we have the right expertise to develop and successfully launch innovative products with the potential to be first and best in class in ophthalmic medicines.”

Mr. Bjarke has held senior roles at Inozyme Pharma, Ophthotech, Alexion Pharmaceuticals, (OSI) Eyetech, and Pharmacia.

David Guyer, MD, Chairman of the Board, added, “The merger of Tenpoint and Visus is a pivotal moment in the evolution of both companies. As Board Chair, I am excited about the opportunity to collaborate with the new leadership team to commercialize Brimochol PF and advance innovative products into clinical development to meet unmet needs in ocular diseases.”

Tenpoint’s pipeline includes three programs aimed at rejuvenating the aging eye:

• Brimochol PF is a once-a-day, all day, presbyopia-correcting eye drop
• TPT-161 is a small molecule designed to reverse cataract formation in aging adults
• TPT-005 is a cell therapy targeting RPE cell replacement for geographic atrophy

Brimochol PF is a combination of carbachol, a miotic, and brimonidine, an alpha2-agonist. This combination is intended to enhance peak efficacy and extend duration and with vasoconstrictive properties of brimonidine, help reduce ocular redness in the treatment of presbyopia, according to a company news release.

Brimochol PF has completed its first phase 3 pivotal trial, BRIO-I, and will complete the second pivotal study, BRIO-II, in 2025. Brimochol PF is on track for filing of an FDA new drug application in 1H 2025. A commercial launch in the United States is anticipated in 1H 2026.

To support the continued development of these programs, Tenpoint will embark on a cossover financing round with insider participation to further fund the completion of clinical studies for Brimochol PF and the commercialization preparations, noted the press release.